PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von María José Jiménez-Santos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. Hauptthemen laut MEDLINE: Multiomics, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, IMPaCT-Data, EU.
Abstract (Originalsprache)
Genomics studies routinely confront researchers with long lists of tumor alterations detected in patients. Such lists are difficult to interpret since only a minority of the alterations are relevant biomarkers for diagnosis and for designing therapeutic strategies. PanDrugs is a methodology that facilitates the interpretation of tumor molecular alterations and guides the selection of personalized treatments. To do so, PanDrugs scores gene actionability and drug feasibility to provide a prioritized evidence-based list of drugs. Here, we introduce PanDrugs2, a major upgrade of PanDrugs that, in addition to somatic variant analysis, supports a new integrated multi-omics analysis which simultaneously combines somatic and germline variants, copy number variation and gene expression data. Moreover, PanDrugs2 now considers cancer genetic dependencies to extend tumor vulnerabilities providing therapeutic options for untargetable genes. Importantly, a novel intuitive report to support clinical decision-making is generated. PanDrugs database has been updated, integrating 23 primary sources that support >74K drug–gene associations obtained from 4642 genes and 14 659 unique compounds. The database has also been reimplemented to allow semi-automatic updates to facilitate maintenance and release of future versions. PanDrugs2 does not require login and is freely available at https://www.pandrugs.org/.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
- CINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, 32004 Ourense, Spain.
- SING Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Vigo, Spain.
ORCID-Profile: Gonzalo Gómez-López, Daniel Glez-Peña, Fátima Al-Shahrour
Förderung
- Instituto de Salud Carlos III
- IMPaCT-Data
- EU
- FEDER
- Agencia Estatal de Investigación
- Ministerio de Ciencia e Innovación
- European Regional Development Fund
- Consellería de Educación
Zitieren
APA
Jiménez-Santos, M. J., Nogueira-Rodríguez, A., Piñeiro-Yáñez, E., López-Fernández, H., García-Martín, S., Gómez-Plana, P., Reboiro-Jato, M., Gómez-López, G., Glez-Peña, D., & Al-Shahrour, F. (2023). PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad412
Vancouver
Jiménez-Santos MJ, Nogueira-Rodríguez A, Piñeiro-Yáñez E, López-Fernández H, García-Martín S, Gómez-Plana P, et al. PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad412
BibTeX
@article{JimnezSantos2023,
author = {Jiménez-Santos, María José and Nogueira-Rodríguez, Alba and Piñeiro-Yáñez, Elena and López-Fernández, Hugo and García-Martín, Santiago and Gómez-Plana, Paula and Reboiro-Jato, Miguel and Gómez-López, Gonzalo and Glez-Peña, Daniel and Al-Shahrour, Fátima},
title = {PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad412}
}
EUVIMED